 |
|
Time Will Be of the Essence in Treating Alzheimer Disease
Commentary by Roger N. Rosenberg, MD
JAMA. 2006;296(3):327-329.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
ARCHIVES OF NEUROLOGY
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid β-Amyloid 42 in Adults With Normal Cognition
Elaine R. Peskind, MD; Ge Li, PhD, MD; Jane Shofer, MS; Joseph F. Quinn, MD; Jeffrey A. Kaye, MD; Chris M. Clark, MD; Martin R. Farlow, MD; Charles DeCarli, MD; Murray A. Raskind, MD; Gerard D. Schellenberg, PhD; Virginia M.-Y. Lee, PhD; Douglas R. Galasko, MD
Background Decreased cerebrospinal fluid (CSF) β-amyloid 42 (Aβ42) concentration, but not Aβ40 concentration, is a biomarker for Alzheimer disease. This Aβ42 concentration decrease in CSF likely reflects precipitation of Aβ42 in amyloid plaques in brain parenchyma. This pathogenic plaque deposition begins years before the clinical expression of dementia in Alzheimer disease. Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease.
Objective To estimate the interactive effects . . . [Full Text of this Article]
Author Affiliations: Department of Neurology, University of Texas Southwestern Medical Center, Dallas.
RELATED ARTICLE
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid  -Amyloid 42 in Adults With Normal Cognition
Elaine R. Peskind, Ge Li, Jane Shofer, Joseph F. Quinn, Jeffrey A. Kaye, Chris M. Clark, Martin R. Farlow, Charles DeCarli, Murray A. Raskind, Gerard D. Schellenberg, Virginia M.-Y. Lee, and Douglas R. Galasko
Arch Neurol. 2006;63(7):936-939.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Measuring the Risk of Alzheimer Disease
Rosenberg
Arch Neurol 2007;64:479-480.
FULL TEXT
|
